Business Context and Reporting Period
Mereo Biopharma Group Plc, a clinical-stage biopharmaceutical company focused on rare diseases, filed this Form 6-K on May 30, 2019. The filing announces positive interim 6-month data from the open-label arm of the Phase 2b "ASTEROID" clinical study evaluating setrusumab (BPS-804) for the treatment of Osteogenesis Imperfecta (OI) in adults.
Key Financial Metrics
The filing text does not provide specific financial values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a clinical data announcement rather than a financial report.
Material Changes and Clinical Data
- Study Progress: The Phase 2b study enrolled 112 patients (69 Type I, 29 Type IV, 14 Type III OI). To date, there have been nine discontinuations.
- Interim Efficacy Data (Open-Label Arm):
- Trabecular Volumetric Bone Mineral Density (Tr vBMD) at Radius: Mean increase of 1.4% at 3 months and 3.2% at 6 months over baseline.
- Areal BMD at Lumbar Spine: Mean increase of 3.5% at 6 months over baseline.
- Comparative Context: The observed increases in Tr vBMD compare favorably to historical data for osteoporosis treatments (alendronate, teriparatide, denosumab), though the sample size (11-12 patients) precludes statistical significance at this stage.
- Safety Profile: The most frequently reported adverse event is headache. There have been no drug-related cardiovascular serious adverse events (SAEs).
Guidance, Outlook, and Management Commentary
- Data Timeline: Mereo expects to report topline 12-month data from the blinded arms of the study in the fourth quarter of 2019.
- Management View: CEO Denise Scots-Knight described the data as "clear and encouraging" and in line with expectations, noting that improvements were observed across all OI subtypes.
- Regulatory Status: The European Medicines Agency (EMA) has approved the Pediatric Investigation Plan (PIP) for setrusumab. A Phase 3 registration study design for pediatric patients (ages 5-18) has been agreed upon.
- Portfolio Updates:
- Alvelestat (AATD): First patient dosed in a Phase 2 U.S. study; data expected end of 2019.
- Acumapimod (COPD): Pivotal Phase 3 study outline announced following a successful FDA Type B meeting.
- Etigilimab (Oncology): Celgene holds an option to license the asset; if exercised, Mereo is eligible for a $35 million payment.
Investor Verification Checklist
- Verify the statistical significance of the 12-month blinded data when released in Q4 2019.
- Confirm the timeline and enrollment status of the pediatric Phase 3 study for setrusumab.
- Monitor the safety profile of setrusumab as the number of patients on treatment for 12 months increases (currently 33 patients).
- Track the progress of the Alvelestat Phase 2 study and the Acumapimod Phase 3 initiation.
- Assess the likelihood of Celgene exercising its option for Etigilimab to realize the potential $35 million payment.